Palatin Technologies (PTN) vs Rocket One (RKTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Palatin Technologies (PTN) has outperformed Rocket One (RKTO) over the past year, gaining 19.4% versus a loss of 61.1%. Over five years, RKTO leads with a -97.8% price change compared with -98.4% for PTN. Rocket One is the larger company by market cap ($16.2 million vs $15.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTN | RKTO |
|---|---|---|
| Share price | $8.60 | $0.6493 |
| Market cap | $15.32M | $16.17M |
| 1-day change | -4.55% | +0.50% |
| YTD return | -44.08% | -34.41% |
| 1-year return | +19.44% | -61.12% |
| 5-year return | -98.40% | -97.76% |
| EPS (TTM) | $-2.96 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.00 | $2.45 |
| 52-week low | $5.61 | $0.489 |
| Distance from 52-week high | -72.26% | -73.50% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +522.09% | — |
| Average volume | 62.75K | 547.04K |
| Shares outstanding | 1.78M | 24.90M |
| Employees | 25 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTN has outperformed RKTO by 80.6 percentage points over the past year.
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PTN vs RKTO FAQ
Which is bigger, Palatin Technologies or Rocket One?
Rocket One (RKTO) is larger, with a market capitalization of $16.17M compared with $15.32M for Palatin Technologies (PTN).
Which stock has performed better over the past year, PTN or RKTO?
PTN returned +19.44% over the past 12 months, compared with -61.12% for RKTO (price return, excluding dividends). Past performance does not predict future results.
Are Palatin Technologies and Rocket One in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.